Evotec Signs Two Significant Contracts with Roche
News May 01, 2006
Evotec AG has announced that it signed two significant service contracts with Roche. These contracts build on the companies’ long-standing relationship and Evotec’s positive contribution to Roche’s discovery projects.
They extend the global medicinal chemistry agreement signed in May 2004 for a further 12 months and its medicinal chemistry collaboration in oncology, signed in October 2003, for an additional 2 years.
In the global medicinal chemistry agreement a team of chemists from Evotec supports all of Roche’s European and US research sites in the design and synthesis of high quality compounds for lead finding and optimization programmes.
In the medicinal chemistry oncology collaboration, both companies aim to identify and develop a clinical lead candidate for a priority target within Roche's oncology research.
Dr Mark Ashton, Executive Vice President Business Development Services at Evotec, said, "We are extremely proud to have been working with Roche since 2001 as one of their preferred partners."
"These significant research programmes announced today are of particular importance for Evotec."
"They emphasise our world leading expertise in medicinal chemistry and the continued trust of our partner Roche. We look forward to continuing to work closely with scientists at Roche for a number of years."
Tuberculosis (TB), an ancient and notoriously difficult disease to treat, has killed millions through the course of human history; and the antibiotics that have been used to fight the disease in recent history are becoming less and less effective. In the face of this reality, researcher Prof. Dennis Wright has improved upon a new way to thwart the tricky pathogen, mycobacterium tuberculosis.READ MORE
Researchers have solved the structures of the cancer-promoting enzymes USP25 and USP28, and identified significant differences in their activities. This knowledge provides the molecular basis for the development of new and highly specific anti-cancer drugs, with a low risk of side-effects.READ MORE